Cover Image
市場調查報告書

Spiriva(氣喘):市場預測與分析

Spiriva (Asthma) - Forecast and Market Analysis to 2023

出版商 GlobalData 商品編碼 316081
出版日期 內容資訊 英文 55 Pages
訂單完成後即時交付
價格
Back to Top
Spiriva(氣喘):市場預測與分析 Spiriva (Asthma) - Forecast and Market Analysis to 2023
出版日期: 2014年08月31日 內容資訊: 英文 55 Pages
簡介

Spiriva(Tiotropium bromide)為Boehringer Ingelheim開發的COPD(慢性阻塞性肺病)治療藥,在全球主要國家上市。這個醫藥品使用持續型的抗蠅蕈鹼/抗膽鹼劑,阻礙呼吸道平滑肌的M3蠅蕈鹼受體,擴張支氣管以便更容易呼吸。根據GlobalData的調查,有部分在藥品仿單核准適應症外使用Spiriva作為中∼重病的持續性氣喘患者治療的案例。

本報告提供氣喘的治療藥之一,Spiriva的全球市場相關分析、氣喘概要和治療方法、競爭的企業與藥品概要、市場競爭概況、Spiriva的商品資訊(特色、功效、安全性等)、全球主要國家的市場販售額預測(今後10年份)等調查,並將結果概述為以下內容。

第1章 目錄

第2章 簡介

  • 分析的背景情況
  • 相關報告
  • 公開預定的相關報告書

第3章 疾病概要

  • 病因與病理學
    • 病因
    • 病理學
    • 預後
    • 生活品質(QoL)
  • 症狀

第4章 疾病管理

  • 診斷及治療概要
    • 診斷
    • 治療指南、臨床診療及代表性的處方藥
    • 臨床診療

第5章 競爭評估

  • 概要
  • 策略性競爭評估

第6章 Spiriva(Tiotropium bromide)

  • 概要
  • 有效性
  • 安全性
  • SWOT分析
  • 預測

第7章 附錄

圖表一覽

目錄

GlobalData has released its new PharmaPoint Drug Evaluation report, "Spiriva (Asthma) - Forecast and Market Analysis to 2023". The asthma market saw very slow growth over the past decade, as it has become saturated with relatively efficacious standard therapies, such as short-acting beta-agonists (SABAs), inhaled corticosteroids (ICSs), inhaled corticosteroids and long-acting beta-agonists (ICS/LABAs), and leukotriene modifiers, and has also been facing increasing generic competition. However, the launch of seven novel targeted biologic agents and once-daily ICS and ICS/LABA therapies delivered by the next-generation inhalers will strongly drive the market growth over the next 10 years. The biologic agents will not only reshape the market growth, but will also mark the beginning of a new era of a personalized approach to asthma treatment. The realization that asthma is a very heterogeneous disease is highly reflected in the rich assortment of these targeted therapies in the late-stage pipeline.

Boehringer Ingelheim's Spiriva (tiotropium bromide) is marketed for the treatment of COPD in all the markets covered by this report. This drug is a long-acting antimuscarinic/anticholinergic agent that causes bronchodilation by inhibiting the M3 muscarinic receptors located in the smooth muscles of the airway. It works by enlarging the airways to allow for easier breathing. GlobalData's primary research revealed that physicians use Spiriva off-label for the treatment of moderate to severe persistent asthma.

Scope

  • Overview of Asthma, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
  • Detailed information on Spiriva including product description, safety and efficacy profiles as well as a SWOT analysis.
  • Sales forecast for Spiriva for the top eight countries from 2013 to 2023.
  • Sales information covered for the US, France, Germany, Italy, Spain, the UK, Japan and Australia.

Reasons to buy

  • Understand and capitalize by identifying products that are most likely to ensure a robust return
  • Stay ahead of the competition by understanding the changing competitive landscape for Asthma
  • Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
  • Make more informed business decisions from insightful and in-depth analysis of Spiriva performance
  • Obtain sales forecast for Spiriva from 2013-2023 in top eight countries (the US, France, Germany, Italy, Spain, the UK, Japan and Australia)

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Catalyst
  • 2.2. Related Reports
  • 2.3. Upcoming Related Reports

3. Disease Overview

  • 3.1. Etiology and Pathophysiology
    • 3.1.1. Etiology
    • 3.1.2. Pathophysiology
    • 3.1.3. Prognosis
    • 3.1.4. Quality of Life
  • 3.2. Symptoms

4. Disease Management

  • 4.1. Diagnosis and Treatment Overview
    • 4.1.1. Diagnosis
    • 4.1.2. Treatment Guidelines, Clinical Practice, and Leading Prescribed Drugs
    • 4.1.3. Clinical Practice

5. Competitive Assessment

  • 5.1. Overview
  • 5.2. Strategic Competitor Assessment

6. Spiriva (tiotropium bromide)

  • 6.1. Overview
  • 6.2. Efficacy
  • 6.3. Safety
  • 6.4. SWOT Analysis
  • 6.5. Forecast

7. Appendix

  • 7.1. Bibliography
  • 7.2. Abbreviations
  • 7.3. Methodology
  • 7.4. Forecasting Methodology
    • 7.4.1. Diagnosed Asthma Patients
    • 7.4.2. Percent Drug-Treated Patients
    • 7.4.3. General Pricing Assumptions
    • 7.4.4. Individual Drug Assumptions
    • 7.4.5. Generic Erosion
  • 7.5. Physicians and Specialists Included in This Study
  • 7.6. About the Authors
    • 7.6.1. Author
    • 7.6.2. Author/Reviewer
    • 7.6.3. Reviewer
    • 7.6.4. Global Head of Healthcare
  • 7.7. About GlobalData
  • 7.8. Disclaimer

List of Tables

  • Table 1: Symptoms of Asthma
  • Table 2: Treatment Guidelines for Asthma by Country
  • Table 3: Most Prescribed Drugs for Asthma by Class and Disease Severity in the Global Markets, 2013
  • Table 4: Dosing of Common ICSs for Adult Asthma Therapy to Achieve Equivalent Therapeutic Potency
  • Table 5: Recommended Low Daily Dose of ICSs in Children with Asthma Under Five Years of Age
  • Table 6: Leading Treatments for Asthma, 2014
  • Table 7: Product Profile - Spiriva
  • Table 8: Efficacy - Spiriva's Versus LABA and Double-Dose ICS
  • Table 9: Adverse Events Related to the Use of Spiriva
  • Table 10: Spiriva SWOT Analysis, 2014
  • Table 11: Global Sales Forecast ($) for Spiriva, 2013-2023
  • Table 12: High-Prescribing Physicians (non-KOLs) Surveyed, By Country

List of Figures

  • Figure 1:Stepwise Disease Management Approach for Asthma in Adults
  • Figure 2: Stepwise Disease Management Approach for Asthma in Children Age Five and Younger
Back to Top